< 生产厂家价格 >

贝诺酯

贝诺酯用途

Benorilate 是对乙酰氨基酚和乙酰水杨酸的酯化产物,具有抗炎、镇痛、解热的作用。Benorilate还能够抑制前列腺素 (PG) 的合成。

点击显示

贝诺酯名称

[ CAS 号 ]:
5003-48-5

[ 中文名 ]:
贝诺酯

[ 英文名 ]:
Benorilate

[中文别名 ]:

[英文别名 ]:

Fenasprate
4'-(Acetamido)phenyl-2-acetoxybenzoate
Fenasparate
4-Acetamidophenyl 2-acetoxybenzoate
p-Acetamidophenyl acetylsalicylate
Benorilate
EINECS 225-674-5
4-(acetylamino)phenyl 2-(acetyloxy)benzoate
Benorylate
MFCD00864257

贝诺酯生物活性

[ 描述 ]:

Benorilate 是对乙酰氨基酚和乙酰水杨酸的酯化产物,具有抗炎、镇痛、解热的作用。Benorilate还能够抑制前列腺素 (PG) 的合成。

[ 相关类别 ]:

信号通路 >> G 蛋白偶联受体/G 蛋白 >> 前列腺素受体

研究领域 >> 炎症/免疫

[ 靶点 ]

Prostaglandin[4].

[体外研究]

Benorilate是一种酯化阿司匹林制剂,其抗风湿特性据报道与阿司匹林一样好[1]。 Benorylate导致肝脏乳酸转化为葡萄糖的大幅度下降,葡萄糖是葡萄糖稳态的重要组成部分。 Benorylate还会损害氨的尿素合成速率,这是肝脏的另一个重要功能[2]。

[体内研究]

Benorylate可能被吸收为完整的分子,这是其良好的胃耐受性[3]。 Benorylate可以抑制实验动物和人体组织中的PG合成[4]。

[参考文献]

[1]. Croft DN, et al. Gastric bleeding and benorylate, a new aspirin. Br Med J. 1972 Sep 2;3(5826):545-7.

[2]. Castell JV, et al. Effects of benorylate and impacina on the metabolism of cultured hepatocytes. Xenobiotica. 1985 Aug-Sep;15(8-9):743-9.

[3]. Wright V, et al. A review of benorylate - a new antirheumatic drug. Scand J Rheumatol Suppl. 1975;13:5-8.

[4]. A. Bennett , et al. Inhibition of Prostaglandin Synthesis by Benorylate. Rheumatology, Volume XII, Issue suppl, 1 January 1973, Pages 101-105.

[相关活性小分子]

贝诺酯物理化学性质

[ 密度 ]:
1.2±0.1 g/cm3

[ 沸点 ]:
511.5±60.0 °C at 760 mmHg

[ 熔点 ]:
177-181ºC

[ 分子式 ]:
C₁₇H₁₅NO₅

[ 分子量 ]:
313.305

[ 闪点 ]:
263.1±32.9 °C

[ 精确质量 ]:
313.095032

[ PSA ]:
81.70000

[ LogP ]:
2.22

[ 外观性状 ]:
固体;White to Almost white powder to crystal

[ 蒸汽压 ]:
0.0±1.4 mmHg at 25°C

[ 折射率 ]:
1.566

[ 储存条件 ]:
室温

贝诺酯毒性和生态

CHEMICAL IDENTIFICATION

RTECS NUMBER :: VO0720000

CHEMICAL NAME :: Salicylic acid, acetate, ester with 4'-hydroxyacetanilide

CAS REGISTRY NUMBER :: 5003-48-5

LAST UPDATED :: 199612

DATA ITEMS CITED :: 6

MOLECULAR FORMULA :: C17-H15-N-O5

MOLECULAR WEIGHT :: 313.33

WISWESSER LINE NOTATION :: 1VOR BVOR DMV1

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Unreported

SPECIES OBSERVED :: Human - woman

DOSE/DURATION :: 1280 mg/kg/8D-I

TOXIC EFFECTS :: Behavioral - hallucinations, distorted perceptions Lungs, Thorax, or Respiration - respiratory stimulation Nutritional and Gross Metabolic - dehydration

REFERENCE :: BMJOAE British Medical Journal. (British Medical Assoc., BMA House, Tavistock Sq., London WC1H 9JR, UK) V.1- 1857- Volume(issue)/page/year: 288,1344,1984

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 3500 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: EPXXDW European Patent Application. (U.S. Patent and Trademark Office, Foreign Patents, Washington, DC 20231) Volume(issue)/page/year: #0080609

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 1830 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: USXXAM United States Patent Document. (U.S. Patent Office, Box 9, Washington, DC 20231) Volume(issue)/page/year: #3431293

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 1551 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 28,1692,1978

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 1255 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: USXXAM United States Patent Document. (U.S. Patent Office, Box 9, Washington, DC 20231) Volume(issue)/page/year: #3431293 ** REPRODUCTIVE DATA **

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 3960 mg/kg

SEX/DURATION :: female 7-17 day(s) after conception

TOXIC EFFECTS :: Reproductive - Specific Developmental Abnormalities - musculoskeletal system

REFERENCE :: SEIJBO Senten Ijo. Congenital Anomalies. (Nippon Senten Ijo Gakkai, c/o Kinki Daigaku Igakubu Kaibagaku Kyoshitsu, 380 Nishiyama, Sayama-cho, Mirami-Kawachi-gun, Osaka-fu, Japan) V.1-26, 1960-86. For publisher information, see CGANE7. Volume(issue)/page/year: 20,143,1980

点击显示

贝诺酯安全信息

[ 危害码 (欧洲) ]:
Xi

[ 海关编码 ]:
2924299090

贝诺酯上下游产品

贝诺酯上游产品

贝诺酯下游产品

贝诺酯海关

[ 海关编码 ]: 2924299090

[ 中文概述 ]:
2924299090. 其他环酰胺（包括环氨基甲酸酯）（包括其衍生物以及他们的盐）. 增值税率:17.0%. 退税率:13.0%. 监管条件:无. 最惠国关税:6.5%. 普通关税:30.0%

[ 申报要素 ]: 品名, 成分含量, 用途, 包装

[ Summary ]:
2924299090. other cyclic amides (including cyclic carbamates) and their derivatives; salts thereof. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:30.0%

贝诺酯